. 2024 Apr 26;10:34. doi: 10.1038/s41523-024-00639-1

Table 4.

Multivariate analysis of factors associated with the risk of discontinuation in abemaciclib-treated patients

Factors		Hazard ratio (95% CI)	Multivariate Model^a,b P value
Geographic region	Asia vs NA/Europe	0.671 (0.541, 0.834)	<0.0001
Geographic region	Other vs NA/Europe	0.672 (0.557, 0.811)	<0.0001
Menopausal status	Post- vs premenopausal	1.514 (1.268, 1.806)	<0.0001
Age group	≥65 years vs <65 years	1.879 (1.566, 2.256)	<0.0001
Baseline ECOG PS	0 vs 1	0.801 (0.662, 0.971)	0.0236
Number of positive nodes	4–9 vs 1–3	0.806 (0.685, 0.949)	<0.0001
Number of positive nodes	≥10 vs 1–3	0.635 (0.514, 0.784)	<0.0001
Number of unique pre-existing comorbidities	1–3 vs 0	1.213 (0.940, 1.566)	0.0004
Number of unique pre-existing comorbidities	≥4 vs 0	1.563 (1.203, 2.032)	0.0004

Data cutoff date: July 01, 2022.

CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, NA North America; vs, versus.

^aIncluded factors with P value < 0.05 in univariate analyses, selected in a stepwise fashion based on a multivariate Cox model, with an entry and retaining P value threshold of 0.05.

^bWald’s P value.